Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beximco PharmaceuticalsBXMPY 94 EV-to-EBITDA is 8.92 as of Aug. 09, 2026, which is 13% below its 10-year median of 10.25. GuruFocus rates BXMPY with a GF Score™ of 94/100. The stock has 5 warning signs investors should review. Among 737 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 84.53% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Beximco Pharmaceuticals's enterprise value is $952.81 Mil.
Beximco Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $106.86 Mil. Therefore, Beximco Pharmaceuticals's EV-to-EBITDA for today is 8.92.
The historical rank and industry rank for Beximco Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
BXMPY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.45 Med: 10.25 Max: 19.59
Current: 5.42
During the past 13 years, the highest EV-to-EBITDA of Beximco Pharmaceuticals was 19.59. The lowest was 3.45. And the median was 10.25.
BXMPY's EV-to-EBITDA is ranked better than 84.53% of 737
companies
in the Drug Manufacturers industry
Industry Median: 13.28
vs BXMPY: 5.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beximco Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Beximco Pharmaceuticals's share price for today is $0.00.
Beximco Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's EV-to-EBITDA falls into.
Beximco Pharmaceuticals's current Enterprise Value is $952.81 Mil.
Beximco Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $106.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (BXMPY) has a EV-to-EBITDA of 8.92 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Beximco Pharmaceuticals. This is 13% below median its historical median of 10.25. Over the past decade, Beximco Pharmaceuticals' EV-to-EBITDA has ranged from 3.45 to 19.59. According to the industry distribution chart, Beximco Pharmaceuticals ranks #114 out of 737 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is Beximco Pharmaceuticals' EV-to-EBITDA too high?
Beximco Pharmaceuticals' current EV-to-EBITDA of 8.92 is 13% below median its 10-year median of 10.25. Over the past 10 years, this metric has ranged from a low of 3.45 to a high of 19.59. The Drug Manufacturers industry median EV-to-EBITDA is 13.28. Beximco Pharmaceuticals' value of 8.92 is 32.8% below this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #114 out of 737 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beximco Pharmaceuticals has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #114 out of 737 companies for EV-to-EBITDA. This places Beximco Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.28. Beximco Pharmaceuticals' value of 8.92 is 32.8% below this benchmark. Historically, Beximco Pharmaceuticals' own EV-to-EBITDA has ranged from 3.45 to 19.59 over the past decade. While the company's 10-year median is 10.25 vs. the industry median of 13.28, Beximco Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.28, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current EV-to-EBITDA of 8.92 is 32.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Beximco Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current EV-to-EBITDA is 8.92, which is 13% below median its own 10-year median of 10.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current EV-to-EBITDA of 8.92. The current EV-to-EBITDA is 8.92, which is 13% below median its 10-year median of 10.25 and 32.8% below the Drug Manufacturers industry median of 13.28. Beximco Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current EV-to-EBITDA is 8.92 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 
